nivolumab,ipilimumab
bms
['niche-2']
2nd presidential #esmo22 symposium now ongoing. moving the use #immunotherapy towards earlier integration into care. i might be biased but i m especially excited about niche-2 presented by #esmo22 
Focused on #PrecisionOncology ?? & #PancreaticCancer ?? •@myesmo faculty •Rolling with @OncoAlert?? •????#MissionCancer Board •Views are my own•